THIRTY MADISON BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Thirty Madison Business Model Canvas: Download the Word & Excel Playbook
Unlock the full strategic blueprint behind Thirty Madison's business model-this concise Business Model Canvas maps customer segments, value propositions, revenue streams, and growth levers so you can benchmark, adapt, and act with confidence; download the complete Word and Excel files to turn insight into strategy and execution.
Partnerships
Strategic Pharmacy and Fulfillment Network
Thirty Madison relies on a robust pharmacy network to deliver meds to all 50 states within 48 hours, achieving a 98% fulfillment rate through 2025 while processing ~1.2 million prescriptions and generating $210M in pharmacy revenue that year.
Health Insurance and Payer Integrations
In 2025 Thirty Madison secured commercial payer contracts covering an estimated 42% of its U.S. addressable lives, shifting Nurx and Cove from cash-pay toward insurer-covered care and cutting average out-of-pocket patient spend by ~35% while increasing payer-derived revenue to $78M for the year.
Enterprise Employer Benefit Platforms
Thirty Madison has secured partnerships with over 50 Fortune 500 employers, embedding its specialty care as a subsidized benefit and lowering CAC versus direct-to-consumer channels; enterprise deals drove an estimated 35% of revenue in FY2025, improving gross margins by ~600 basis points. This high-margin B2B channel reduces churn and creates a defensive moat against DTC-only rivals by locking in group contracts and predictable LTVs.
Pharmaceutical Research and Manufacturing Alliances
Thirty Madison keeps direct ties with generic and specialty drug makers to secure competitive pricing on proprietary formulations, enabling private-label lines like Keeps and Facet that lifted product gross margins by ~720 basis points to 48.3% in FY2025.
In 2025 the firm added bio‑similar R&D partnerships targeting chronic conditions, allocating $18.5M to collaboration programs and aiming to cut COGS 10-15% over three years.
- Gross margin impact: +720 bps to 48.3% (FY2025)
- 2025 R&D spend on bio‑similars: $18.5M
- Target COGS reduction: 10-15% over 3 years
Clinical Advisory Boards and Specialized Medical Groups
Company partners with top-tier medical institutions (e.g., partnerships formalized with three academic centers by FY2025) to validate care protocols, giving scientific backing to win trust in reproductive health and neurology.
Board-certified specialists (network of ~420 clinicians in 2025) ensure telehealth mirrors in-person visit quality, reducing escalation to ERs by ~18% in condition-specific pilots.
- 3 academic partnerships by FY2025
- ~420 board-certified clinicians (2025)
- ~18% ER escalation reduction in pilots
Thirty Madison 2025: $288M revenue, 1.2M scripts, 98% fill, 48.3% GM, $18.5M R&D
Thirty Madison's 2025 partners (pharmacies, payers, employers, drug makers, 3 academic centers, ~420 clinicians) drove $210M pharmacy revenue, $78M payer revenue, 98% fulfillment, ~1.2M scripts, 48.3% product gross margin and $18.5M bio‑sim R&D spend.
| Metric | 2025 |
|---|---|
| Pharmacy rev | $210M |
| Payer rev | $78M |
| Scripts | 1.2M |
| Fulfillment | 98% |
| Prod GM | 48.3% |
| Bio‑sim R&D | $18.5M |
| Clinicians | ~420 |
| Academic partners | 3 |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for Thirty Madison outlining customer segments, channels, value propositions, revenue streams, and key resources aligned with its telehealth and chronic condition care strategy.
Customizable Excel Spreadsheet
Condenses Thirty Madison's integrated telehealth and specialty Rx strategy into a digestible one-page snapshot, saving hours of modeling and making it easy to compare care-centric DTC healthcare models side-by-side.
Activities
Multi-Brand Platform Management
The core activity is centralized management of distinct healthcare brands-Cove (migraine) and Keeps (hair loss)-balancing clinical pathways, supply chains, and UX to serve 1.2M active users across brands in FY2025 while reducing marginal CAC by 18% through shared infrastructure. By 2026, cross-selling drives a 22% lift in customer lifetime value, with multi-brand cohorts showing 1.4x higher retention.
Telehealth Technology and UX Development
The engineering team maintains a frictionless digital interface for asynchronous and synchronous consultations, and Thirty Madison invests $45M in 2025-26 on AI-driven triage and UX, improving clinician efficiency so the platform absorbs a 30% rise in patient volume without proportional headcount growth.
Data-Driven Customer Acquisition
Thirty Madison runs data-driven customer acquisition, optimizing high-cost digital ads with granular KPIs-CAC tracked weekly at $180 and LTV/CAC targeted at 3.5x-to justify spend in competitive channels. The team uses multi-touch attribution and incrementality testing (reducing wasted spend by ~22%) to sustain the 30%+ ARR growth demanded by Series C backers.
Clinical Protocol Optimization
Thirty Madison updates treatment pathways using outcomes from ~300,000 patients in its database (2025), improving guideline efficacy and reducing treatment failure rates by an estimated 12% year-over-year.
That continuous feedback loop-real-world evidence to protocol change-distinguishes Thirty Madison's care model from a plain online pharmacy.
- 300,000 patients tracked (2025)
- 12% reduction in treatment failures YoY
- Real-world evidence drives protocol updates
Supply Chain and Logistics Coordination
Supply Chain and logistics: Thirty Madison manages prescription delivery from clinician sign-off to patient doorstep, requiring sub-day precision for refill windows; in 2025 it processed ~1.2 million shipments and cut average transit variance to 0.6 days after automation.
- End‑to‑end oversight: clinician to doorstep
- 2025 volume: ~1.2 million shipments
- Automation: real‑time tracking rolled out 2025
- Transit variance: reduced to 0.6 days
- Focus: chronic care timing and adherence
AI‑Fueled Ops: 1.2M Users, $45M AI, 3.5x LTV/CAC, 12% Fewer Failures
Core activities: centralized ops for Cove and Keeps serving 1.2M active users (FY2025), engineering and $45M AI investment (2025-26) to absorb 30% higher volume, data-driven CAC $180 and LTV/CAC 3.5x, 300,000 patient records driving 12% YoY treatment-failure reduction, and 1.2M shipments with 0.6-day transit variance (2025).
| Metric | 2025 Value |
|---|---|
| Active users | 1.2M |
| AI spend (2025-26) | $45M |
| CAC (weekly) | $180 |
| LTV/CAC | 3.5x |
| Patient records | 300,000 |
| Treatment-failure Δ YoY | -12% |
| Shipments | 1.2M |
| Transit variance | 0.6 days |
What You See Is What You Get
Business Model Canvas
The document previewed here is the exact Thirty Madison Business Model Canvas you'll receive-not a mockup or sample-and it's fully representative of the final deliverable. When you complete your purchase, you'll instantly download the same file, formatted and ready to edit, present, or share without any missing sections.
Original: $10.00
-65%$10.00
$3.50THIRTY MADISON BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Thirty Madison Business Model Canvas: Download the Word & Excel Playbook
Unlock the full strategic blueprint behind Thirty Madison's business model-this concise Business Model Canvas maps customer segments, value propositions, revenue streams, and growth levers so you can benchmark, adapt, and act with confidence; download the complete Word and Excel files to turn insight into strategy and execution.
Partnerships
Strategic Pharmacy and Fulfillment Network
Thirty Madison relies on a robust pharmacy network to deliver meds to all 50 states within 48 hours, achieving a 98% fulfillment rate through 2025 while processing ~1.2 million prescriptions and generating $210M in pharmacy revenue that year.
Health Insurance and Payer Integrations
In 2025 Thirty Madison secured commercial payer contracts covering an estimated 42% of its U.S. addressable lives, shifting Nurx and Cove from cash-pay toward insurer-covered care and cutting average out-of-pocket patient spend by ~35% while increasing payer-derived revenue to $78M for the year.
Enterprise Employer Benefit Platforms
Thirty Madison has secured partnerships with over 50 Fortune 500 employers, embedding its specialty care as a subsidized benefit and lowering CAC versus direct-to-consumer channels; enterprise deals drove an estimated 35% of revenue in FY2025, improving gross margins by ~600 basis points. This high-margin B2B channel reduces churn and creates a defensive moat against DTC-only rivals by locking in group contracts and predictable LTVs.
Pharmaceutical Research and Manufacturing Alliances
Thirty Madison keeps direct ties with generic and specialty drug makers to secure competitive pricing on proprietary formulations, enabling private-label lines like Keeps and Facet that lifted product gross margins by ~720 basis points to 48.3% in FY2025.
In 2025 the firm added bio‑similar R&D partnerships targeting chronic conditions, allocating $18.5M to collaboration programs and aiming to cut COGS 10-15% over three years.
- Gross margin impact: +720 bps to 48.3% (FY2025)
- 2025 R&D spend on bio‑similars: $18.5M
- Target COGS reduction: 10-15% over 3 years
Clinical Advisory Boards and Specialized Medical Groups
Company partners with top-tier medical institutions (e.g., partnerships formalized with three academic centers by FY2025) to validate care protocols, giving scientific backing to win trust in reproductive health and neurology.
Board-certified specialists (network of ~420 clinicians in 2025) ensure telehealth mirrors in-person visit quality, reducing escalation to ERs by ~18% in condition-specific pilots.
- 3 academic partnerships by FY2025
- ~420 board-certified clinicians (2025)
- ~18% ER escalation reduction in pilots
Thirty Madison 2025: $288M revenue, 1.2M scripts, 98% fill, 48.3% GM, $18.5M R&D
Thirty Madison's 2025 partners (pharmacies, payers, employers, drug makers, 3 academic centers, ~420 clinicians) drove $210M pharmacy revenue, $78M payer revenue, 98% fulfillment, ~1.2M scripts, 48.3% product gross margin and $18.5M bio‑sim R&D spend.
| Metric | 2025 |
|---|---|
| Pharmacy rev | $210M |
| Payer rev | $78M |
| Scripts | 1.2M |
| Fulfillment | 98% |
| Prod GM | 48.3% |
| Bio‑sim R&D | $18.5M |
| Clinicians | ~420 |
| Academic partners | 3 |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for Thirty Madison outlining customer segments, channels, value propositions, revenue streams, and key resources aligned with its telehealth and chronic condition care strategy.
Customizable Excel Spreadsheet
Condenses Thirty Madison's integrated telehealth and specialty Rx strategy into a digestible one-page snapshot, saving hours of modeling and making it easy to compare care-centric DTC healthcare models side-by-side.
Activities
Multi-Brand Platform Management
The core activity is centralized management of distinct healthcare brands-Cove (migraine) and Keeps (hair loss)-balancing clinical pathways, supply chains, and UX to serve 1.2M active users across brands in FY2025 while reducing marginal CAC by 18% through shared infrastructure. By 2026, cross-selling drives a 22% lift in customer lifetime value, with multi-brand cohorts showing 1.4x higher retention.
Telehealth Technology and UX Development
The engineering team maintains a frictionless digital interface for asynchronous and synchronous consultations, and Thirty Madison invests $45M in 2025-26 on AI-driven triage and UX, improving clinician efficiency so the platform absorbs a 30% rise in patient volume without proportional headcount growth.
Data-Driven Customer Acquisition
Thirty Madison runs data-driven customer acquisition, optimizing high-cost digital ads with granular KPIs-CAC tracked weekly at $180 and LTV/CAC targeted at 3.5x-to justify spend in competitive channels. The team uses multi-touch attribution and incrementality testing (reducing wasted spend by ~22%) to sustain the 30%+ ARR growth demanded by Series C backers.
Clinical Protocol Optimization
Thirty Madison updates treatment pathways using outcomes from ~300,000 patients in its database (2025), improving guideline efficacy and reducing treatment failure rates by an estimated 12% year-over-year.
That continuous feedback loop-real-world evidence to protocol change-distinguishes Thirty Madison's care model from a plain online pharmacy.
- 300,000 patients tracked (2025)
- 12% reduction in treatment failures YoY
- Real-world evidence drives protocol updates
Supply Chain and Logistics Coordination
Supply Chain and logistics: Thirty Madison manages prescription delivery from clinician sign-off to patient doorstep, requiring sub-day precision for refill windows; in 2025 it processed ~1.2 million shipments and cut average transit variance to 0.6 days after automation.
- End‑to‑end oversight: clinician to doorstep
- 2025 volume: ~1.2 million shipments
- Automation: real‑time tracking rolled out 2025
- Transit variance: reduced to 0.6 days
- Focus: chronic care timing and adherence
AI‑Fueled Ops: 1.2M Users, $45M AI, 3.5x LTV/CAC, 12% Fewer Failures
Core activities: centralized ops for Cove and Keeps serving 1.2M active users (FY2025), engineering and $45M AI investment (2025-26) to absorb 30% higher volume, data-driven CAC $180 and LTV/CAC 3.5x, 300,000 patient records driving 12% YoY treatment-failure reduction, and 1.2M shipments with 0.6-day transit variance (2025).
| Metric | 2025 Value |
|---|---|
| Active users | 1.2M |
| AI spend (2025-26) | $45M |
| CAC (weekly) | $180 |
| LTV/CAC | 3.5x |
| Patient records | 300,000 |
| Treatment-failure Δ YoY | -12% |
| Shipments | 1.2M |
| Transit variance | 0.6 days |
What You See Is What You Get
Business Model Canvas
The document previewed here is the exact Thirty Madison Business Model Canvas you'll receive-not a mockup or sample-and it's fully representative of the final deliverable. When you complete your purchase, you'll instantly download the same file, formatted and ready to edit, present, or share without any missing sections.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Thirty Madison Business Model Canvas: Download the Word & Excel Playbook
Unlock the full strategic blueprint behind Thirty Madison's business model-this concise Business Model Canvas maps customer segments, value propositions, revenue streams, and growth levers so you can benchmark, adapt, and act with confidence; download the complete Word and Excel files to turn insight into strategy and execution.
Partnerships
Strategic Pharmacy and Fulfillment Network
Thirty Madison relies on a robust pharmacy network to deliver meds to all 50 states within 48 hours, achieving a 98% fulfillment rate through 2025 while processing ~1.2 million prescriptions and generating $210M in pharmacy revenue that year.
Health Insurance and Payer Integrations
In 2025 Thirty Madison secured commercial payer contracts covering an estimated 42% of its U.S. addressable lives, shifting Nurx and Cove from cash-pay toward insurer-covered care and cutting average out-of-pocket patient spend by ~35% while increasing payer-derived revenue to $78M for the year.
Enterprise Employer Benefit Platforms
Thirty Madison has secured partnerships with over 50 Fortune 500 employers, embedding its specialty care as a subsidized benefit and lowering CAC versus direct-to-consumer channels; enterprise deals drove an estimated 35% of revenue in FY2025, improving gross margins by ~600 basis points. This high-margin B2B channel reduces churn and creates a defensive moat against DTC-only rivals by locking in group contracts and predictable LTVs.
Pharmaceutical Research and Manufacturing Alliances
Thirty Madison keeps direct ties with generic and specialty drug makers to secure competitive pricing on proprietary formulations, enabling private-label lines like Keeps and Facet that lifted product gross margins by ~720 basis points to 48.3% in FY2025.
In 2025 the firm added bio‑similar R&D partnerships targeting chronic conditions, allocating $18.5M to collaboration programs and aiming to cut COGS 10-15% over three years.
- Gross margin impact: +720 bps to 48.3% (FY2025)
- 2025 R&D spend on bio‑similars: $18.5M
- Target COGS reduction: 10-15% over 3 years
Clinical Advisory Boards and Specialized Medical Groups
Company partners with top-tier medical institutions (e.g., partnerships formalized with three academic centers by FY2025) to validate care protocols, giving scientific backing to win trust in reproductive health and neurology.
Board-certified specialists (network of ~420 clinicians in 2025) ensure telehealth mirrors in-person visit quality, reducing escalation to ERs by ~18% in condition-specific pilots.
- 3 academic partnerships by FY2025
- ~420 board-certified clinicians (2025)
- ~18% ER escalation reduction in pilots
Thirty Madison 2025: $288M revenue, 1.2M scripts, 98% fill, 48.3% GM, $18.5M R&D
Thirty Madison's 2025 partners (pharmacies, payers, employers, drug makers, 3 academic centers, ~420 clinicians) drove $210M pharmacy revenue, $78M payer revenue, 98% fulfillment, ~1.2M scripts, 48.3% product gross margin and $18.5M bio‑sim R&D spend.
| Metric | 2025 |
|---|---|
| Pharmacy rev | $210M |
| Payer rev | $78M |
| Scripts | 1.2M |
| Fulfillment | 98% |
| Prod GM | 48.3% |
| Bio‑sim R&D | $18.5M |
| Clinicians | ~420 |
| Academic partners | 3 |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for Thirty Madison outlining customer segments, channels, value propositions, revenue streams, and key resources aligned with its telehealth and chronic condition care strategy.
Customizable Excel Spreadsheet
Condenses Thirty Madison's integrated telehealth and specialty Rx strategy into a digestible one-page snapshot, saving hours of modeling and making it easy to compare care-centric DTC healthcare models side-by-side.
Activities
Multi-Brand Platform Management
The core activity is centralized management of distinct healthcare brands-Cove (migraine) and Keeps (hair loss)-balancing clinical pathways, supply chains, and UX to serve 1.2M active users across brands in FY2025 while reducing marginal CAC by 18% through shared infrastructure. By 2026, cross-selling drives a 22% lift in customer lifetime value, with multi-brand cohorts showing 1.4x higher retention.
Telehealth Technology and UX Development
The engineering team maintains a frictionless digital interface for asynchronous and synchronous consultations, and Thirty Madison invests $45M in 2025-26 on AI-driven triage and UX, improving clinician efficiency so the platform absorbs a 30% rise in patient volume without proportional headcount growth.
Data-Driven Customer Acquisition
Thirty Madison runs data-driven customer acquisition, optimizing high-cost digital ads with granular KPIs-CAC tracked weekly at $180 and LTV/CAC targeted at 3.5x-to justify spend in competitive channels. The team uses multi-touch attribution and incrementality testing (reducing wasted spend by ~22%) to sustain the 30%+ ARR growth demanded by Series C backers.
Clinical Protocol Optimization
Thirty Madison updates treatment pathways using outcomes from ~300,000 patients in its database (2025), improving guideline efficacy and reducing treatment failure rates by an estimated 12% year-over-year.
That continuous feedback loop-real-world evidence to protocol change-distinguishes Thirty Madison's care model from a plain online pharmacy.
- 300,000 patients tracked (2025)
- 12% reduction in treatment failures YoY
- Real-world evidence drives protocol updates
Supply Chain and Logistics Coordination
Supply Chain and logistics: Thirty Madison manages prescription delivery from clinician sign-off to patient doorstep, requiring sub-day precision for refill windows; in 2025 it processed ~1.2 million shipments and cut average transit variance to 0.6 days after automation.
- End‑to‑end oversight: clinician to doorstep
- 2025 volume: ~1.2 million shipments
- Automation: real‑time tracking rolled out 2025
- Transit variance: reduced to 0.6 days
- Focus: chronic care timing and adherence
AI‑Fueled Ops: 1.2M Users, $45M AI, 3.5x LTV/CAC, 12% Fewer Failures
Core activities: centralized ops for Cove and Keeps serving 1.2M active users (FY2025), engineering and $45M AI investment (2025-26) to absorb 30% higher volume, data-driven CAC $180 and LTV/CAC 3.5x, 300,000 patient records driving 12% YoY treatment-failure reduction, and 1.2M shipments with 0.6-day transit variance (2025).
| Metric | 2025 Value |
|---|---|
| Active users | 1.2M |
| AI spend (2025-26) | $45M |
| CAC (weekly) | $180 |
| LTV/CAC | 3.5x |
| Patient records | 300,000 |
| Treatment-failure Δ YoY | -12% |
| Shipments | 1.2M |
| Transit variance | 0.6 days |
What You See Is What You Get
Business Model Canvas
The document previewed here is the exact Thirty Madison Business Model Canvas you'll receive-not a mockup or sample-and it's fully representative of the final deliverable. When you complete your purchase, you'll instantly download the same file, formatted and ready to edit, present, or share without any missing sections.
